News | June 02, 2025
Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Annual EBITDA margin expands by 170 basis points
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Akums invested Rs. 272 crore in capital expenditure during FY25
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
Subscribe To Our Newsletter & Stay Updated
